Polymyxin-dextran antiendotoxin pretreatment in an ovine model of normotensive sepsis

Critical Care Medicine

Volumn 25, Issue 12, 1997, Pages 1956-1961

  Doig, Gordon S ^b   Martin, Claudio M ^b   Sibbald, William J ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

Edema; Endothelium; Morphometry; Muscle; Polymyxin; Randomize d control trial; Sepsis; Sheep; Therapy

Indexed keywords

DEXTRAN; ENDOTOXIN ANTIBODY; HEMOGLOBIN; LACTIC ACID; PLACEBO; POLYMYXIN B; SERUM ALBUMIN;

ABDOMINAL INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEVER; GASTROCNEMIUS MUSCLE; INDWELLING CATHETER; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; MUSCLE BIOPSY; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; SEPSIS; SHEEP;

ANIMALS; ANTI-BACTERIAL AGENTS; DEXTRANS; ENDOTOXINS; HEMODYNAMIC PROCESSES; MALE; MUSCLES; PLASMA SUBSTITUTES; POLYMYXIN B; PREMEDICATION; SEPSIS; SHEEP;

EID: 0031437073     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199712000-00009     Document Type: Article

References (26)

1. Morisaki H, Bloos F, Keys J, et al: Compared with crystalloid, colloid therapy slows progression of extrapulmonary tissue injury in septic sheep. J Appl Physiol 1994; 77:1507-1518
2. Greenman RL, Schein RM, Martin MA, et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA sepsis study. JAMA 1991; 266:1097-1102
3. Ziegler EJ, Fisher CJ, Sprung CL, et al: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1991; 324:429-436
4. Marra MN, Thornton MB, Snable BS, et al: Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit Care Med 1994; 22:559-565
5. Van Dervort AL, Danner RL: Anti-endotoxin approaches to septic shock therapy. Crit Care Med 1994; 22: 539-540
6. Cooperstock MS: Inactivation of endotoxin by polymyxin B. Antimicrob Agents Chemother 1974; 6:422-425
7. Palmer JD, Rifkind D: Neutralization of the hemodynamic effects of endotoxin by Polymyxin B. Surg Gynecol Obstet 1974; 138:755-759
8. Bucklin SE, Lake P, Logdberg L, et al: Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia. Antimicrob Agents Chemother 1995; 39:1462-1466
9. Hess ML, Nastillo A, Greenfield LJ: Spectrum of cardiovascular function during Gram-negative sepsis. Prog Cardiovasc Dis 1981; 4:279-298
10. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
11. Opal SM: Clinical trials of novel therapeutic agents: Why did they fail? In: 1995 Yearbook of Intensive Care and Emergency Medicine. Vincent J-L (Ed). New York, Springer-Verlag, 1995, pp 425-436
12. Fox GA, Lam C, Darrah W, et al: Circulatory sequelae of administering PEEP in hyperdynamic sepsis are time-dependent. J Appl Physiol 1996; 181:976-984
13. Kloner RA, Rude RE, Carlson N, et al: Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: Which comes first? Circulation 1980; 62:945-952
14. Bakker J, Coffernils M, Leon M, et al: Blood lactate levels are superior to oxygen derived variables in predicting outcome in human septic shock. Chest 1991; 99:956-962
15. Snedecor GW, Cochran WG: Levene's test of homogeneity of variance. In: Statistical Methods. Eighth Edition. Ames, IA, Iowa State University Press, 1991, pp 252-253
16. Hersch M, Gnidec AA, Bersten AD, et al: Histologic and ultrastructural changes in nonpulmonary organs during early hyperdynamic sepsis. Surgery 1990; 107:397-410
17. Flamand FJ, Sibbald WJ, Girotti MJ, et al: Pentoxifylline does not prevent microvascular injury in normotensive, septic rats. Crit Care Med 1995; 23:119-124
18. Gnidec AG, Sibbald WJ, Cheung H, et al: Ibuprofen reduces the progression of permeability edema in an animal model of hyperdynamic sepsis. J Appl Physiol 1988; 65:1024-1032
19. Jennings RB, Ganote CE: Mitochondrial structure and function in acute myocardial ischemic injury. Circ Res 1976; 38:(Suppl I):80-91
20. Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B: Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. J Biol Chem 1992; 267:5317-5323
21. Stadler J, Bentz BG, Harcrecht BG: Tumor necrosis factor alpha inhibits hepatocyte mitochondrial respiration. Ann Surg 1992; 216:539-546
22. Cumming AD: Changes in plasma calcium during septic shock. J Accident Emerg Med 1994; 11:3-7
23. Vincent J-L: The at risk patient population. In: Update in Intensive Care and Emergency Medicine. Vol 29. Clinical Trials for the Treatment of Sepsis. Sibbald WJ, Vincent J-L (Eds). New York, Springer-Verlag, 1995, pp 13-34
24. Kreger BE, Craven DE, McCabe WR: Gram-negative bacteremia: Re-evaluation of clinical features and treatment in 6123 patients. Am J Med 1980; 68:344-355
25. Bryan CS, Reynolds KL, Brenner ER: Analysis of 1186 episodes of Gram-negative bacteremia in non-university hospitals: The effect of antimicrobial therapy. Rev Infect Dis 1983; 13:34-46
26. Gasche Y, Pittet D, Suter PM: Outcome and prognostic factors in bacteremic sepsis. In: Update in Intensive Care and Emergency Medicine. Vol 20. Clinical Trials for the Treatment of Sepsis. Vincent J-L, Sibbald WJ (Eds). New York, Springer-Verlag, 1995, pp 14-35